IN VITRO ANTI-INFLAMMATORY AND HEPATOPROTECTIVE ACTIVITY OF TURMESAC®

  • FIROZ H. M. Star Hi Herbs Pvt Ltd, Plot No. 50, 3rd Road, 1st Phase, KIADB Industrial Area, Jigani Bangalore 560105, Karnataka, India
  • NANJUNDAIAH S. Star Hi Herbs Pvt Ltd, Plot No. 50, 3rd Road, 1st Phase, KIADB Industrial Area, Jigani Bangalore 560105, Karnataka, India
  • SADASHIVA C. T. Star Hi Herbs Pvt Ltd, Plot No. 50, 3rd Road, 1st Phase, KIADB Industrial Area, Jigani Bangalore 560105, Karnataka, India

Abstract

Objective: In this study, we investigated the hepatoprotective activity of Turmesac® on Human liver cells (HepG2 cell line) and anti-inflammatory effect on Murine macrophages (Raw 264.7 cell line) by flow Cytometry.


Methods: Cell viability of HepG2 and Raw 264.7 cells determined by the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay to identify a non-cytotoxic concentration of Turmesac® for the respective cell lines after 24 h exposure period. Further hepatoprotective effect of Turmesac® was performed in H2O2 treated liver cells using H2DCF-DA staining by flow cytometry. The anti-inflammatory potency of Turmesac® was evaluated in Lipopolysaccharide (LPS 2µg/ml) stimulated Murine Raw 264.7 macrophages by measuring the relative fluorescence intensity of 2 cytokines, Interleukin-8(IL-8) and (Interleukin-12) IL-12 by flow cytometric analysis.


Results: Turmesac® concentrations of less than 50μg/ml did not show significant cytotoxicity on both HepG2 and Raw 264.7, cell lines following the treatment period of 24 h and selected 50μg/ml as the optimum concentration for hepatoprotective and anti-inflammatory models. The reactive oxygen species (ROS) study revealed that Turmesac® (50μg/ml) effectively suppressed the H2DCF-DA expression in HepG2 cells. Secondly, Turmesac® significantly suppressed the anti-inflammatory cytokine expressions of IL-8 and IL-12 in LPS pre-stimulated cells categorising as a potentially potent anti-inflammatory drug. The mean fluorescence intensity percentage of IL-8 is control 8.86, LPS 50.49, Turmesac® 19.63 and IL12 is control 10.41, LPS 68.94, and Turmesac® 15.79 respectively.


Conclusion: This study highlighted that Turmesac® could be considered as a promising hepatoprotective and anti-inflammatory compound and a therapeutic agent in curing liver-related and inflammation-related diseases.

Keywords: Nil, HepG2, Raw 264.7, MTT, Flow cytometry, IL-8, IL-12, Hepatoprotective, H2DCFDA and anti-inflammatory

Downloads

Download data is not yet available.

References

1. Hewlings SJ, Kalman DS. Curcumin: a review of its' effects on human health. Foods 2017;10:92.
2. Chainani Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 2003;1:161-8.
3. Ammon H, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991;57:1-7.
4. Thakur R, Puri HS, Husain A. Major medicinal plants of India. Lucknow: Central Institute of Medicinal and Aromatic Plants; 1989. p. 585.
5. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013;15:195–218.
6. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental Mendia LE, Majeed M, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: a post-hoc analysis of a randomized controlled trial. Biomed Pharmacother 2016;82:578–82.
7. Mazzolani F, Togni S. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy. A 12-month follow-up study. Clin Ophthalmol 2013;7:939–45.
8. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: Efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol 2010;4:1201–6.
9. Trujillo J, Chirino YI, Molina Jijon E, Anderica Romero AC, Tapia E, Pedraza Chaverri J. Renoprotective effect of the antioxidant curcumin recent findings. Redox Biol 2013;1:448–56.
10. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40–59.
11. Kohli K, Ali J, Ansari MJ, Raheman Z. Curcumin: a natural antiinflammatory agent. Indian J Pharmacol 2005;37 Suppl 141-7.
12. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009;14:141-53.
13. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008;11:1631-52.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
15. Barzegar A, Moosavi Movahedi AA. Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PLoS One 2011;6:e26012.
16. Chandrasekaran C, Sundarajan K, Edwin J, Gururaja G, Mundkinajeddu D, Agarwal A. Immune-stimulatory and anti-inflammatory activities of Curcuma longa extract and its polysaccharide fraction. Pharmacognosy Res 2013;5:71–9.
17. Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi BVV, Khar A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett 1999;456:311–4.
18. Widowati W, Sardjono CT, Wijaya L, Laksmitawati DR, Darsono L. Free radicals scavenging activities of spices and curcumin. Proc Second Int Symp Temulawak 2001;178–81. https://doi.org/10.1155/2017/8471785
19. Sadashiva CT, Firoz Hussain HM, Nanjundaiah S. Evaluation of hepatoprotective, antioxidant and cytotoxic properties of aqueous extract of turmeric rhizome (Turmesac ®). J Med Plants Res 2019;13:423–30.
Statistics
71 Views | 97 Downloads
Citatons
How to Cite
H. M., F., N. S., and S. C. T. “IN VITRO ANTI-INFLAMMATORY AND HEPATOPROTECTIVE ACTIVITY OF TURMESAC®”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 9, July 2020, pp. 49-53, doi:10.22159/ijpps.2020v12i9.38173.
Section
Original Article(s)